Diaceutics PLC (LON:DXRX – Get Free Report) insider Nick Roberts purchased 112 shares of the company’s stock in a transaction on Monday, September 30th. The shares were bought at an average cost of GBX 134 ($1.79) per share, with a total value of £150.08 ($200.75).
Nick Roberts also recently made the following trade(s):
- On Wednesday, August 28th, Nick Roberts bought 113 shares of Diaceutics stock. The stock was purchased at an average cost of GBX 134 ($1.79) per share, with a total value of £151.42 ($202.54).
Diaceutics Price Performance
Shares of LON:DXRX opened at GBX 133.99 ($1.79) on Wednesday. The company has a market cap of £113.18 million, a P/E ratio of -4,466.00 and a beta of 0.58. The business has a fifty day simple moving average of GBX 128.87 and a 200-day simple moving average of GBX 120.22. Diaceutics PLC has a 52 week low of GBX 82 ($1.10) and a 52 week high of GBX 136 ($1.82). The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93.
Wall Street Analyst Weigh In
View Our Latest Research Report on DXRX
Diaceutics Company Profile
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
Featured Articles
- Five stocks we like better than Diaceutics
- Options Trading – Understanding Strike Price
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Stocks to Consider Buying in October
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Stock Market Sectors: What Are They and How Many Are There?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.